CTTH (CTT Pharmaceutical Holdings) Pre-Tax Income: $-0.21 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings Pre-Tax Income?

CTT Pharmaceutical Holdings CTTH -2.52% Pre-Tax Income is $-0.21 Mil as of Mar. 2026. The stock has 1 warning sign investors should review.

Pretax income is the income that a company earns before paying income taxes. CTT Pharmaceutical Holdings's pretax income for the three months ended in Mar. 2026 was $-0.09 Mil. Its pretax income for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.21 Mil. CTT Pharmaceutical Holdings's pretax margin was %.


CTT Pharmaceutical Holdings  (OTCPK:CTTH) Pre-Tax Income Explanation

CTT Pharmaceutical Holdings's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pretax Income/Revenue
=-0.085/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CTT Pharmaceutical Holdings Pre-Tax Income Related Terms


CTT Pharmaceutical Holdings Pre-Tax Income Historical Data

* Premium members only.

The historical data trend for CTT Pharmaceutical Holdings's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CTT Pharmaceutical Holdings Pre-Tax Income Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 0.23 -1.45 -0.25 -0.16

CTT Pharmaceutical Holdings Quarterly Data
Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Mar17 Jun17 Mar18 Jun18 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.06 -0.02 -0.05 -0.09

CTTH vs AKAN, SBFM, PRFX: Pre-Tax Income Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTT Pharmaceutical Holdings Pre-Tax Income vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where CTT Pharmaceutical Holdings's Pre-Tax Income falls into.



CTT Pharmaceutical Holdings Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

CTT Pharmaceutical Holdings's Pretax Income for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.154+0+-0.002+0+0
=-0.16

CTT Pharmaceutical Holdings's Pretax Income for the quarter that ended in Mar. 2026 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-0.085+0+0+0+0
=-0.09

Pre-Tax Income for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pre-Tax Income →
What does a Pre-Tax Income of $-0.21 Mil mean?
CTT Pharmaceutical Holdings (CTTH) has a Pre-Tax Income of $-0.21 Mil as of Mar. 2026. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on CTT Pharmaceutical Holdings and its competitors.
Is CTT Pharmaceutical Holdings' Pre-Tax Income too high?
CTT Pharmaceutical Holdings' current Pre-Tax Income is $-0.21 Mil.
How does CTT Pharmaceutical Holdings' Pre-Tax Income compare to AKAN and SBFM?
CTT Pharmaceutical Holdings' Pre-Tax Income of $-0.21 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pre-Tax Income for a Drug Manufacturers company?
A good Pre-Tax Income depends on the Drug Manufacturers industry context. However, Pre-Tax Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pre-Tax Income mean?
A high Pre-Tax Income can signal that a stock is expensive relative to its fundamentals. Pre-Tax Income is the total earnings before taxes but after all operating and interest expenses. View historical data on CTT Pharmaceutical Holdings and its competitors. CTT Pharmaceutical Holdings's current Pre-Tax Income is $-0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current Pre-Tax Income of $-0.21 Mil. The current Pre-Tax Income is $-0.21 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pre-Tax Income calculated?
Pre-Tax Income is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current Pre-Tax Income is $-0.21 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.